DEF0008417MA - - Google Patents
Info
- Publication number
- DEF0008417MA DEF0008417MA DEF0008417MA DE F0008417M A DEF0008417M A DE F0008417MA DE F0008417M A DEF0008417M A DE F0008417MA
- Authority
- DE
- Germany
- Prior art keywords
- pig
- swine fever
- viruses
- weakened
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000282898 Sus scrofa Species 0.000 claims description 69
- 241000700605 Viruses Species 0.000 claims description 48
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 38
- 241000282887 Suidae Species 0.000 claims description 36
- 206010037660 Pyrexia Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 28
- 241000710777 Classical swine fever virus Species 0.000 claims description 25
- 230000002238 attenuated effect Effects 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 230000003053 immunization Effects 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 15
- 210000000952 spleen Anatomy 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 14
- 210000002751 lymph Anatomy 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 8
- 210000001550 testis Anatomy 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 17
- 239000012895 dilution Substances 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 230000036039 immunity Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 14
- 206010035148 Plague Diseases 0.000 description 9
- 241000607479 Yersinia pestis Species 0.000 description 9
- 239000000463 material Substances 0.000 description 6
- 208000003322 Coinfection Diseases 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 230000003313 weakening effect Effects 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000512613 Liasis Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69215355T2 (de) | Stabilisierter Varizella-Lebendimpfstoff | |
| DE2606118A1 (de) | Gamma-globuline fuer intravenoese injektion und verfahren zur herstellung von solchem gamma-globulin | |
| DE2421083A1 (de) | Verfahren zur herstellung von vaccinen | |
| DE69923470T2 (de) | Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion | |
| DE69432665T3 (de) | Multikomponentenimpfstoff aus clostridien, der saponin als adjuvans benutzt | |
| DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE2444299A1 (de) | Impfstoffe gegen katzen-leukaemie | |
| DE60031243T2 (de) | Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant | |
| DE69636001T2 (de) | Multikomponentimpfstoff aus niedrigdosierten Clostridien und Nicht-Clostridien-Organismen | |
| DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
| DE2816942C2 (de) | Impfstoff gegen Rhinitis atrophicans beim Schwein | |
| DE940315C (de) | Verfahren zur Herstellung von Lymphe gegen Schweinepest | |
| DE3122669A1 (de) | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" | |
| DE1950774A1 (de) | Heteroploide Zellinien | |
| DE1492243C3 (de) | Injizierbare Impfstoffe | |
| DEF0008417MA (enExample) | ||
| DE833673C (de) | Verfahren zur Herstellung einer Schweinecholera-Lymphe | |
| DE2700338C2 (de) | Parenteral injizierbarer Impfstoff für Schweine gegen Infektionen von Bordetella bronchiseptica sowie Verfahren zum Herstellen dieses Impfstoffes | |
| DE191752C (enExample) | ||
| DE2923333C2 (de) | Sterilisierung von Säugern | |
| DE2134930A1 (de) | Antigene Extrakte | |
| DE2057544B2 (de) | Impfstoff gegen ein neonatales Kälberdiarrhoevirus, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE2034118A1 (en) | Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins | |
| DE2225548A1 (de) | Intravenoes vertraegliche staupe- und hepatitisvaccine | |
| DE3028248A1 (de) | Emulgierte antigenzubereitung aus bacteroides nodosus und aluminiumadjuvans und ihre verwendung als impfstoff |